Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

iology and Hypertension Program and Professor of Medicine at the University of Alabama at Birmingham in Alabama. "In addition to important blood pressure lowering, the combination of Tekturna and Diovan maintained a tolerability profile similar to that seen with either agent alone," said Dr. Oparil.

Tekturna received U.S. regulatory approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. This once-daily oral therapy is expected to be available by the end of March in U.S. pharmacies as 150 mg and 300 mg tablets.

A second study presented at the meeting compared Tekturna (150 mg or 300 mg alone or 300 mg in combination with HCTZ) to ramipril (5 mg or 10 mg alone or 10 mg in combination with HCTZ), another high blood pressure medicine in a class known as angiotensin converting enzyme (ACE) inhibitors (ACC presentation #1014). Results showed 61.4% of patients treated with the Tekturna-based therapy reached their blood pressure goal vs. 53.1% of patients treated with the ramipril-based therapy.

Tekturna and Diovan should be discontinued as soon as pregnancy is detected as they may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna or Diovan.

The need for new high blood pressure medicines is urgent given that this condition affects one in three adults in the U.S. and nearly 70% of these patients remain uncontrolled. In fact, many require two or more medications to reach their target blood pressure goal. Uncontrolled high blood pressure can increase the risk of cardiovascular disease, the world's leading cause of death.

"We are very encouraged by these results since they show Tekturna and Diovan are effective w
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
(Date:11/24/2014)... Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... , President and CEO of Inovio Pharmaceuticals, will be joined ... ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, ... th listing on the Nasdaq Global Select Market.  ... said, "We are honored to ring the Nasdaq Opening Bell ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
(Date:11/23/2014)... -- Close friends have more influence on teens, alcohol ... study says. "We,ve known for a long ... individual alcohol use, but there are no common studies ... friend group,s influence on those decisions," Jonathon Beckmeyer, an ... said in a university news release. Beckmeyer analyzed ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, ... the new products are available at low rates up ... proud of the new emergency doors. The emergency door ... can choose from several colors. All of the products ... door release is not as easy as many people ...
(Date:11/23/2014)... show thanks to new and old customers, iFitDress.com has ... for weddings. Customers who need custom outfits can talk ... dress manufacturer, and it is among the ones which have ... long time. The CEO of this company says, "iFitDress.com is ... buy not only a beautiful dress, but also a piece ...
(Date:11/23/2014)... York, NY (PRWEB) November 23, 2014 ... the past month in a federal litigation involving Byetta ... similar diabetes medications, Bernstein Liebhard LLP reports. , ... 566 claims over a class of Type 2 diabetes ... filed in the U.S. District Court, Southern District of ...
(Date:11/23/2014)... 23, 2014 Asher Milgrom, is ... & Wellness was recently featured on International ... president and CEO of American Medical Aesthetics & Wellness, ... received a full scholarship to attend an M.D./Ph.D program ... at the University of Chicago, where his field of ...
Breaking Medicine News(10 mins):Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... FRIDAY, March 25 (HealthDay News) -- Even very young ... negative emotions toward them, researchers confirm. The new ... harmless, but stress-inducing, situations, such as causing them to ... saliva samples were taken from the children to measure ...
... FRIDAY, March 25 (HealthDay News) -- Most people want to ... through with healthy lifestyle habits, finds a new survey. ... found that 93.3 percent of respondents believe they are more ... said their doctor was more responsible and 2.3 percent didn,t ...
... Reporter , FRIDAY, March 25 (HealthDay News) -- Teen superstar Nick ... ago his body was wasting away. Even at 13, Jonas knew ... something was type 1 diabetes, and though it,s a disease Jonas ... because he spends a lot of time every day taking care ...
... Food and Drug Administration today approved the use of ipilimumab ... the first drug approved for metastatic, or advanced, melanoma is ... a new class of drugs that has been shown to ... a fatal disease, and hopefully, this will lead to the ...
... York, NY, Mar. 25, 2011 The U.S. Food and ... treatment for advanced melanoma, the deadliest and most difficult-to-treat form ... is the first treatment of any kind ever shown in ... improve overall survival in patients with metastatic melanoma who no ...
... News) -- Seniors who suffer elder abuse are more likely ... and to abuse drugs or alcohol, new research indicates. ... Chicago-area trauma units and compared 41 cases of elder abuse ... group) who were treated between 1999 and 2006. The ...
Cached Medicine News:Health News:Study Highlights How Moms' Depression, Anger Stresses Kids 2Health News:Nick Jonas Lives Large, Despite Diabetes 2Health News:Nick Jonas Lives Large, Despite Diabetes 3Health News:FDA approves new drug for advanced melanoma 2Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 2Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 3Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 4Health News:Alcohol May Play Dual Role in Some Cases of Elder Abuse 2
... a rapid qualitative test for detection of ... serum samples. It can be used as ... infarction and can be useful to assess ... non-cardiac angina (e.g. gastric pain, strained chest ...
...
...
...
Medicine Products: